Durable Response to Vemurafenib and Cobimetinib for the Treatment of BRAF-Mutated Metastatic Melanoma in Routine Clinical Practice

Autor: Monica Corral, Fernando Garicano, Pedro López, Begoña Campos Balea, Eva Muñoz-Couselo, Javier Medina, Guillermo Crespo, Analia Rodríguez Garzotto, Pilar Sancho, Mª del Carmen Álamo, Sebastian Ochenduszko, Juana Oramas
Přispěvatelé: Institut Català de la Salut, [Álamo MC] Oncology Department, Hospital Universitario Virgen Macarena, Sevilla, Spain. [Ochenduszko S] Oncology Department, Hospital Universitario Dr. Peset, Valencia, Spain. [Crespo G] Oncology Department, Hospital Universitario de Burgos, Burgos, Spain. [Corral M] Oncology Department, Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain. [Oramas J] Oncology Department, Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain. [Sancho P] Oncology Department, Hospital Universitario Virgen del Rocío, Sevilla, Spain. [Muñoz-Couselo E] Servei d’Oncologia Mèdica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain, Vall d'Hebron Barcelona Hospital Campus
Jazyk: angličtina
Rok vydání: 2021
Předmět:
Oncology
medicine.medical_specialty
Neoplasms::Neoplasms by Histologic Type::Neoplasms::Neoplasms by Histologic Type::Neoplasms::Neoplasms by Histologic Type::Nevi and Melanomas::Melanoma [DISEASES]
Metastatic melanoma
Otros calificadores::Otros calificadores::/farmacoterapia [Otros calificadores]
Other subheadings::Other subheadings::/drug therapy [Other subheadings]
OncoTargets and Therapy
BRAF
chemistry.chemical_compound
Metàstasi
durable response
Internal medicine
Medicine
Pharmacology (medical)
Routine clinical practice
Vemurafenib
cobimetinib
Original Research
Cobimetinib
business.industry
Melanoma - Tractament
Neoplasms::Neoplastic Processes::Neoplasm Metastasis [DISEASES]
diagnóstico::pronóstico::resultado del tratamiento [TÉCNICAS Y EQUIPOS ANALÍTICOS
DIAGNÓSTICOS Y TERAPÉUTICOS]
Diagnosis::Prognosis::Treatment Outcome [ANALYTICAL
DIAGNOSTIC AND THERAPEUTIC TECHNIQUES
AND EQUIPMENT]
humanities
clinical practice
chemistry
neoplasias::procesos neoplásicos::metástasis neoplásica [ENFERMEDADES]
Avaluació de resultats (Assistència sanitària)
vemurafenib
business
neoplasias::neoplasias por tipo histológico::neoplasias::neoplasias por tipo histológico::neoplasias::neoplasias por tipo histológico::nevos y melanomas::melanoma [ENFERMEDADES]
medicine.drug
metastatic melanoma
Zdroj: OncoTargets and therapy
Scientia
ISSN: 1178-6930
Popis: Mª del Carmen Álamo,1 Sebastian Ochenduszko,2 Guillermo Crespo,3 Mónica Corral,4 Juana Oramas,5 Pilar Sancho,6 Javier Medina,7 Fernando Garicano,8 Pedro López,9 Begoña Campos Balea,10 Analia Rodríguez Garzotto,11 Eva Muñoz-Couselo12,13 1Oncology Department, Hospital Universitario Virgen Macarena, Sevilla, Spain; 2Oncology Department, Hospital Universitario Dr. Peset, Valencia, Spain; 3Oncology Department, Hospital Universitario de Burgos, Burgos, Spain; 4Oncology Department, Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain; 5Oncology Department, Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain; 6Oncology Department, Hospital Universitario Virgen del Rocío, Sevilla, Spain; 7Oncology Department, Hospital Universitario Virgen de la Salud, Toledo, Spain; 8Oncology Department, Hospital de Galdakao, Bizkaia, Spain; 9Oncology Department, Complejo Hospitalario General de Jaén, Jaén, Spain; 10Oncology Department, Hospital Lucus Augusti, Lugo, Spain; 11Medical Department and Strategy, Roche S.A, Madrid, Spain; 12Oncology Department, Hospital Universitario Vall d´Hebron, Barcelona, Spain; 13VHIO Vall d’Hebron Institute on Oncology, Barcelona, SpainCorrespondence: Eva Muñoz-CouseloOncology Department, Hospital Universitario Vall d´Hebron, Passeig de la Vall d’Hebron, 119, Barcelona, 08035, SpainEmail emunoz@vhio.netBackground: The combination of BRAF and MEK inhibitors delays the onset of resistance and provides more sustained and dramatic responses in comparison with a BRAF inhibitor in monotherapy. The objective of the study was to evaluate the effectiveness of the combination therapy with vemurafenib/cobimetinib in terms of durability, and to describe differential characteristics in patients associated to durable responses in real-world settings.Patients and Methods: Retrospective, observational, cross-sectional, multicenter study involving 41 patients with advanced melanoma harboring a BRAFV600 mutation who initiated a combination therapy with vemurafenib/cobimetinib between May 2018 and March 2019. Participants were differentiated regarding the durability of the response: durable (complete response, CR, or a partial response, PR, for at least 12 months) and non-durable (stable disease, SD, progressive disease, PD, or CR/PR < 12 months). Secondary endpoints included treatment adherence, labor productivity, anxiety/depression, and safety profile.Results: During the combination therapy, 12 patients (29.3%) had a CR, 19 a PR (46.3%), 5 showed SD (12.2%), and 5 had PD. A total of 12 patients (29.3%) were considered as achieving a durable response and 29 (70.7%) as a non-durable one. Practically all sociodemographic and clinical characteristics were similar between patients. Body mass index was the only differential factor (with higher body mass index achieving a non-durable response). The treatment adherence was 100% in patients with durable response and 66.7% in those with non-durable.Conclusion: The combination treatment with vemurafenib/cobimetinib results in an important impact on long-term survival, leading to a steady CR in one-third of the patients.Keywords: vemurafenib, cobimetinib, BRAF, metastatic melanoma, durable response, clinical practice
Databáze: OpenAIRE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje